Search Results

You are looking at 181 - 190 of 2,671 items for :

  • Refine by Access: All x
Clear All
Full access

Chunkit Fung, Paul C. Dinh Jr, Sophie D. Fossa, and Lois B. Travis

long-term adverse health outcomes (AHOs) among TCS is critically important for the development of risk-stratified, evidence-based follow-up guidelines. A multi-institutional study 40 among North American TCS (median age, 37 years) after cisplatin

Full access

Jacqueline Agustin and Ma. Rosario Irene D. Castillo

not eligible for transplant, hence chemotherapy is a frequently chosen alternative. This meta-analysis sheds light on treatment outcomes of advanced stage myeloproliferative neoplasm patients treated with combination decitabine and ruxolitinib

Full access

Davide Mauri, Antonis Valachis, Nikolaos P. Polyzos, Lamprini Tsali, Dimitris Mavroudis, Vassilis Georgoulias, and Giovanni Casazza

-analysis calculations. Data Extraction and Outcomes Information recorded from each eligible trial included author names; journal; year of publication; number of centers involved; number of patients randomly assigned and analyzed per arm; years of patient

Full access

Pamala A. Pawloski, Cara L. McDermott, James H. Marshall, Vanita Pindolia, Catherine M. Lockhart, Catherine A. Panozzo, Jeffrey S. Brown, and Bernadette Eichelberger

use in real-world settings are maturing, and critical pharmacovigilance of these products depends on the understanding of their use and clinical impact. 30 , 31 Similar clinical and safety outcomes of the G-CSF biosimilars compared with their

Full access

Abdenour Nabid, Nathalie Carrier, Eric Vigneault, André-Guy Martin, Thu Van Nguyen, Jean-Paul Bahary, Peter Vavassis, Marc-André Brassard, Sylvie Vass, Boris Bahoric, Robert Archambault, Francois Vincent, Redouane Bettahar, Marie Duclos, Derek Wilke, and Luis Souhami

Purpose/Objective(s): To compare the magnitude of differences in outcomes between intermediate and high risk prostate cancer (IRPC – HRPC) using NCCN classification in two concurrent phase III trials performed in the same population. Materials

Full access

Harrys A. Torres, Parag Mahale, Boris Blechacz, Ethan Miller, Ahmed Kaseb, H. Franklin Herlong, Nathan Fowler, Ying Jiang, Issam I. Raad, and Dimitrios P. Kontoyiannis

natural history, management, and outcome. Professional societies have published guidelines for the diagnosis, management, and treatment of HCV infection, 9 specific sections of which address immunocompromised patients, such as HIV coinfected patients and

Full access

Raymond Elsoueidi, Jessica Craig, Hesham Mourad, and Elie M. Richa

Infusional 5-FU monotherapy has been used in patients with severe liver dysfunction, but the clinical outcomes have been disappointing. 8 FOLFOX and FOLFIRI have resulted in superior responses and survival rates compared with 5-FU alone. 9 However, the

Full access

Matthew E. Nielsen, Bruce J. Trock, and Patrick C. Walsh

within 2 years of biochemical recurrence. Additionally, consistent with other studies examining biochemical outcome after salvage RT, the survival benefit in this study cohort was seen only among men whose PSA became undetectable after salvage RT. 9

Full access

Cole Friedes, Nick Mai, Wei Fu, Peijin Han, Ranh Voong, and Russell Hales

Background: Although isolated locoregional recurrence (iLR) for non-small cell lung cancer (NSCLC) is relatively common, the optimal therapy for iLR is undefined. It is feasible that patients with iLR may have equal or superior outcomes to patients

Full access

Jeffrey Zhong, Jaime Abe Perez, Annie Liang Zhang, Debora Bruno, and Melinda Laine-Hsu

mortality when compared to non-Asian patients with EGFR-positive NSCLC in a real-world US population. Further research is required to determine whether this association stems from a biological or non-biological cause. Table. Outcomes between AANHPI